Bifogade filer
Updated Financial Calendar for 2022 (H1 update)
Kurs
+2,08%
Likviditet
0,17 MDKK
Kalender
| Tid* | ||
| 2025-08-08 | 17:00 | Kvartalsrapport 2025-Q2 |
| 2025-03-26 | N/A | Årsstämma |
| 2025-02-28 | 07:00 | Bokslutskommuniké 2024 |
| 2024-08-20 | - | Kvartalsrapport 2024-Q2 |
| 2024-05-17 | - | X-dag ordinarie utdelning STRAP 0.00 DKK |
| 2024-04-11 | - | Årsstämma |
| 2024-04-04 | - | Bokslutskommuniké 2023 |
| 2023-12-06 | - | Split STRAP 1000:1 |
| 2023-11-02 | - | Extra Bolagsstämma 2023 |
| 2023-09-12 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-22 | - | X-dag ordinarie utdelning STRAP 0.00 DKK |
| 2023-05-17 | - | Årsstämma |
| 2023-04-25 | - | Bokslutskommuniké 2022 |
| 2022-09-26 | - | Kvartalsrapport 2022-Q2 |
| 2022-06-29 | - | Årsstämma |
| 2022-06-28 | - | X-dag ordinarie utdelning STRAP 0.00 DKK |
| 2022-06-07 | - | Bokslutskommuniké 2021 |
| 2022-02-15 | - | Extra Bolagsstämma 2022 |
| 2021-08-31 | - | Kvartalsrapport 2021-Q2 |
| 2021-03-26 | - | X-dag ordinarie utdelning STRAP 0.00 DKK |
| 2021-03-25 | - | Årsstämma |
| 2021-03-02 | - | Bokslutskommuniké 2020 |
| 2020-09-21 | - | Extra Bolagsstämma 2020 |
| 2020-08-28 | - | Kvartalsrapport 2020-Q2 |
| 2020-03-27 | - | X-dag ordinarie utdelning STRAP 0.00 DKK |
| 2020-03-26 | - | Årsstämma |
| 2020-02-28 | - | Bokslutskommuniké 2019 |
| 2020-01-25 | - | Extra Bolagsstämma 2019 |
| 2019-08-28 | - | Kvartalsrapport 2019-Q2 |
| 2019-03-28 | - | X-dag ordinarie utdelning STRAP 0.00 DKK |
| 2019-03-27 | - | Årsstämma |
| 2019-03-01 | - | Bokslutskommuniké 2018 |
| 2018-08-28 | - | Kvartalsrapport 2018-Q2 |
| 2018-04-13 | - | X-dag ordinarie utdelning STRAP 0.00 DKK |
| 2018-04-12 | - | Årsstämma |
| 2018-03-15 | - | Bokslutskommuniké 2017 |
Beskrivning
| Land | Danmark |
|---|---|
| Lista | Small Cap Copenhagen |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Company announcement
Orphazyme A/S
No. 34/2022
www.orphazyme.com
Company Registration No. 32266355
Copenhagen, Denmark, September 19, 2022 – Orphazyme A/S (ORPHA.CO) (the “Company”) announces an update to the Company’s financial calendar in regard to the publication of the Company’s Interim Report First Half 2022. The Interim Report First Half 2022 will be published on September 26, 2022, previously September 20, 2022. Additional time is required to conclude the presentation of the financial statements following the sale of substantially all Orphazyme’s assets and business activities to KemPharm Denmark A/S, a wholly owned subsidiary of KemPharm, Inc. (KMPH: NASDAQ, NY) which completed during the reporting period.
Interim Report First Half 2022
September 26, 2022
For additional information, please contact
Orphazyme A/S
Anders Vadsholt, Chief Executive Officer and Chief Financial Officer +45 28 98 90 55